Key result
Imipramine and desipramine are linked to 2 fatal cases of hypersensitivity myocarditis and hepatitis.
Case Report (n=2)
This report provides the first evidence associating imipramine and its metabolite desipramine with potentially fatal hypersensitivity myocarditis and hepatitis.
Answers are grounded in this paper and cite their sources.
May warrant vigilance in imipramine users with unexplained myocarditis; leaves open causality and generalizability.
We present two cases of myocarditis and hepatitis with histologic characteristics of hypersensitivity-mediated drug reactions associated with imipramine and its metabolite, desipramine. In one case, death was directly attributed to myocarditis; in the second case, the patient died of an acute myocardial infarct, but myocarditis may have played a contributory role. One patient was taking imipramine, and therapeutic concentrations of imipramine and desipramine were documented in postmortem blood. The other patient was receiving desipramine documented by in-patient hospital medication records. Both cases had liver lesions associated in the medical literature with adverse drug reaction to imipramine. Although myocarditis has been previously associated with amitriptyline, these cases appear to be the first reported in association with imipramine/desipramine. The fact that one patient was taking only desipramine suggests that it may be the offending agent.
No takes yet. Share an insight, caveat, or question.
Morrow et al. (1989) conducted a case report in Hypersensitivity myocarditis and hepatitis (n=2). Imipramine and desipramine was evaluated on Myocarditis and hepatitis. Imipramine and its metabolite desipramine were associated with two fatal cases of hypersensitivity myocarditis and hepatitis.
Synapse has enriched 10 related papers. Consider them for comparative context: